← Eichor
Study identifier: NCT06358625 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer

Condition: HER2-positive Breast Cancer  ·  Sponsor: Center Eugene Marquis

PhaseN/A
Planned participants120
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

HER2 gene amplification, detected in 20% to 30% of breast cancers, was a poor prognostic factor before the advent of anti-HER2 therapies. In the early 2000s, trastuzumab revolutionised the management of patients with HER2-positive (HER2+) breast cancer in the metastatic and localised stages of the disease. At the time of diagnosis of metastatic disease, 7-11% of patients have brain metastases, with (70% of cases) or without symptoms (30% of cases). In the absence of brain metastases, 30% to 50% of patients will develop brain metastases within the first two years of treatment, depending on whether the disease is hormone receptor positive (HR+) or negative (HR-). The presence of brain metastases is the most important prognostic factor. The neurological symptoms caused by the presence of these lesions, but also by the local treatments offered, affect patients' quality of life, although improvements in surgical and radiotherapy techniques have significantly reduced the need for particularly toxic whole brain radiotherapy. International guidelines do not recommend systematic brain MRI in the absence of neurological symptoms, either in the adjuvant or metastatic stages of this disease. However, there may be a role for more systematic and earlier screening for cerebral recurrence, as single cerebral recurrences without extracranial involvement are common and the new anti-HER2 agents (i.e. tucatinib, an anti-HER2 tyrosine kinase inhibitor, and T-Dxd) have shown significant objecti…

This description comes directly from the study's public registry record.

Talk to the study team

Valérie JOLAINE, Dr  ·  (0)299253036  ·  v.jolaine@rennes.unicancer.fr

Marion TROCHET  ·  (0)299253165  ·  m.trochet@rennes.unicancer.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Centre de lutte contre le cancer Eugène MarquisRennes, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06358625